FIELD: biotechnology; medicine.
SUBSTANCE: invention relates to medical biotechnology. Disclosed is a polypeptide having immunity-inducing activity against PDS5A protein, selected from a group of polypeptides consisting of amino acid sequences presented by SEQ ID NO: 20–67. Disclosed is a composition having immunity-inducing activity against PDS5A protein. Composition contains at least one polypeptide as an active ingredient. Polypeptide has immunity-inducing activity against PDS5A protein and is selected from a group of polypeptides consisting of amino acid sequences represented by SEQ ID NO: 20–67. Disclosed is a composition having immunity-inducing activity against PDS5A protein. Composition contains a recombinant vector as an active ingredient, which contains at least one polynucleotide coding at least one polypeptide selected from a group of polypeptides consisting of amino acid sequences presented by SEQ ID NO: 20–67.
EFFECT: polypeptide can be used as an active ingredient in an agent for treating or preventing a malignant tumour, as well as an immunity inducer.
9 cl, 8 dwg, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IMMUNITY INDUCER | 2016 |
|
RU2758112C2 |
| T-CELL RECEPTORS RECOGNIZING R175H OR Y220C MUTATION IN p53 | 2020 |
|
RU2830061C2 |
| ARTIFICIAL ANTIGEN-PRESENTING CELLS AND METHODS FOR THEIR APPLICATION | 2018 |
|
RU2763798C1 |
| T-CELL RECEPTOR CONSTRUCTS AND THEIR USE | 2019 |
|
RU2785954C2 |
| IMMUNO-INDUCING AGENT | 2016 |
|
RU2744843C2 |
| NEUTRALIZATION OF LYMPHOCYTE INHIBITORY PATHWAYS | 2015 |
|
RU2734771C2 |
| CANCER TREATMENT USING ANTI-NKG2A AGENTS | 2015 |
|
RU2721271C2 |
| PEPTIDE DERIVED FROM FOXM1, AND INCLUDING ITS VACCINE | 2016 |
|
RU2738418C2 |
| CHIMERIC ANTIGENIC (CAR) RECEPTOR AGAINST CD123 FOR USE IN TREATING MALIGNANT TUMORS | 2015 |
|
RU2724999C2 |
| TREATMENT OF MALIGNANT NEOPLASM USING HUMANIZED CHIMERIC ANTIGEN RECEPTOR AGAINST BCMA | 2015 |
|
RU2751660C2 |
